GlycoMimetics, Inc. (GLYC)

Market Cap	19.31M
Revenue (ttm)	10,000
Net Income (ttm)	-37.28M
Shares Out	64.46M
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,529,066
Open	0.283
Previous Close	0.281
Day's Range	0.283 - 0.310
52-Week Range	0.260 - 3.530
Beta	2.29
Analysts	Buy
Price Target	12.00 (+3,908.02%)
Earnings Date	May 9, 2024

About GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protei...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 10, 2014
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: GLYC

Financial Performance

In 2023, GlycoMimetics's revenue was $10,000, a decrease of -86.67% compared to the previous year's $75,000. Losses were -$36.90 million, -20.97% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for GLYC stock is "Buy." The 12-month stock price forecast is $12.0, which is an increase of 3,908.02% from the latest price.

Price Target

$12.0

(3,908.02% upside)

Analyst Consensus: Buy